Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.729
Filter
2.
Vitae (Medellín) ; 29(1): 1-9, 2022-01-09. Ilustraciones
Article in English | LILACS, COLNAL | ID: biblio-1363761

ABSTRACT

Background: Diabetes mellitus treatment is based on oral hypoglycemic agents or insulin. Medicinal plants constitute an option, and the leaves of Prosopis ruscifolia (Pr) were shown to be effective in reducing glycemia in hyperglycemic animals. Objective: In this paper, we report the effect of P. rusciofolia (Pr) on insulin and incretin secretion in alloxan-induced hyperglycemic rats. Methodology: The effective dose was selected, and four groups (n=10) of Wistar rats were used. Two groups with normal glycemia received water or Pr (75 mg/Kg, per os, p.o.), and two groups with hyperglycemia induced by alloxan (intraperitoneal, ip), received water or Pr (75 mg/Kg, p.o.) for 2 weeks. Oral glucose tolerance test, and incretin and insulin levels were measured at the end of the experimental period. Results: The results showed that extract promotes better tolerance to oral glucose overload, in addition to a statistically significant (p<0.001) increase in blood levels of incretin and insulin, compared to the hyperglycemic rats. Conclusion: It is concluded that the ethanolic extract of P. ruscifolialeaves has a hypoglycemic effect in hyperglycemic animals by a mechanism that involves the incretin-insulin system


Antecedentes: la diabetes mellitus es una enfermedad metabólica cuyo tratamiento se basa en el uso de agentes hipoglicemiantes orales o insulina. Una opción al tratamiento son las plantas medicinales y en ese sentido, estudios previos en animales con hojas de Prosopis ruscifolia (Pr) han demostrado efecto hipoglicemiante. Objetivo: en este trabajo se reporta el efecto de P. rusciofolia (Pr) en la secreción de insulina e incretina, en ratas hiperglicémicas por aloxano. Metodología: se emplearon cuatro grupos de ratas Wistar (n=10). Dos grupos con glicemia normal que fueron tratadas con agua Pr (75 mg/Kg, per os, p.o.) y dos grupos con hiperglicemia inducida por la inyección intraperitoneal de aloxano recibieron agua Pr (75 mg/Kg, per os, p.o.) durante dos semanas. Se midieron la tolerancia oral a la glucosa, y los niveles de incretina e insulina al final del periodo de experimentación. Resultados: se encontró que el extracto promueve una mayor tolerancia a la sobrecarga de glucosa, y además un incremento significativo (p<0.001) de los niveles de incretina e insulina en sangre, comparados al grupo de ratas hiperglicémicas. Conclusión: se concluye que e l estracto etanólico de las hojas de P. ruscifolia tienen efecto hipoglicemiante en animales hiperglicémicos por un mecanismo que incluye al sistema incretina-insulina


Subject(s)
Humans , Hyperglycemia , Biochemical Phenomena , Incretins , Insulin
3.
Braz. J. Pharm. Sci. (Online) ; 58: e18893, 2022. tab, graf
Article in English | LILACS | ID: biblio-1364414

ABSTRACT

Abstract On the increasing prevalence of using mAbs (monoclonal antibodies) in cancer therapy and the severe risk of hyperglycemia, we aimed to analyze the main clinical ADRs of mAbs, with a focus on adverse hyperglycemic events associated with currently clinically used mAbs. mAbs as well as target information were selected from Martinadale book and published articles. Drug approving information was collected from each government website, and ADR statistic data were collected from VigibaseR, comparing with Adverse Event Reporting System of US FDA. Top 10 mAbs were classified within listing in total ADR records, ADRs per year, hyperglycemic ADR records. Vigibase data were updated onto 15 Feb 2019. 20 mAbs were analyzed with 263217 ADR reports, wherein 16751 records on Metabolism and nutrition disorders and 1444 records on Glucose metabolism disorders. The geographic, age, gender distributions and annual ADR report numbers were listed respectively. Of the top 10, Rituximab, Bevacizumab and Nivolumab were on the top 3 in total ADR record and hyperglycemic record. Top 3 record results were similar in Vigibase and FDA database. It is of increasing importance for clinicians to be aware of early detection, patient management, or drug selection strategies when using mAbs, particularly within the high glycemic risk-reported mAbs, to improve the efficacy and tolerability of mAbs regiment and optimize patient outcomes.


Subject(s)
Blood Glucose/analysis , Glucose Metabolism Disorders/pathology , Drug-Related Side Effects and Adverse Reactions , Research Report , Rituximab , Glucose/adverse effects , Hyperglycemia , Antibodies, Monoclonal/classification , Patients/statistics & numerical data , Computer Communication Networks/instrumentation , Efficacy/statistics & numerical data , Health Strategies , Antibodies, Monoclonal , Neoplasms
4.
Arch. pediatr. Urug ; 92(2): e305, dic. 2021. tab
Article in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1278305

ABSTRACT

Las afecciones respiratorias agudas son la primera causa de consulta e ingreso hospitalario en los meses de invierno, y entre ellas el asma ocupa un lugar preponderante. El salbutamol es un broncodilatador con eficacia demostrada en las exacerbaciones y se utiliza de primera línea en el tratamiento. El objetivo de la presente comunicación es analizar dos casos clínicos de niños asmáticos que presentaron efectos adversos al salbutamol y requirieron el ingreso en la Unidad de Terapia Intensiva. Se propone revisar los efectos adversos del salbutamol empleado en crisis asmáticas y analizar las alternativas terapéuticas en esta enfermedad. Los síntomas de los efectos secundarios pueden confundirse con los causados por la propia enfermedad, por lo que puede usarse el fármaco de modo excesivo y es importante conocer el perfil posológico y caracterizar los posibles efectos secundarios en los pacientes para usar de manera racional y segura este medicamento.


Acute respiratory conditions are the first cause of consultation and hospital admission in the Winter months, being asthma the most important. Salbutamol is a bronchodilator with proven efficacy in exacerbations used first-line in treatment. The objective of this paper is to analyze two clinical cases of asthmatic children who presented adverse effects to salbutamol and required admission to the Intensive Care Unit. It is proposed to review the adverse effects of salbutamol used in asthmatic crises and to analyze therapeutic alternatives in this disease. Symptoms of side effects can be confused with those caused by the disease itself, determining the excessive use of this drug, thus, it is important to know the dosage profile and characterize the possible side effects to make rational and safe use of this drug.


As doenças respiratórias agudas são a primeira causa de consultas e internações nos meses de inverno e a asma ocupa é a mais importante. O salbutamol é um broncodilatador com eficácia comprovada nas exacerbações e é usado como tratamento de primeira linha. O objetivo desta comunicação é analisar dois casos clínicos de crianças asmáticas que apresentaram efeitos adversos ao salbutamol e necessitaram de internação em Unidade de Terapia Intensiva. Propõe-se revisar os efeitos adversos do salbutamol utilizado na crise asmática e analisar as alternativas terapêuticas nessa doença. Os sintomas de efeitos colaterais podem ser confundidos com os causados pela própria doença, determinando o uso excessivo desse medicamento, sendo importante conhecer o perfil posológico e caracterizar os possíveis efeitos colaterais nos pacientes para fazer um uso racional e seguro desse medicamento.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Acidosis, Lactic , Bronchodilator Agents/adverse effects , Albuterol/adverse effects , Hyperglycemia/chemically induced , Hypokalemia/chemically induced , Psychomotor Agitation/etiology , Recurrence , Asthma/drug therapy , Tachycardia/chemically induced , Tremor/chemically induced , Hallucinations/chemically induced
5.
Rev. baiana saúde pública ; 45(3,supl.n.esp): 8-23, 28 dec. 2021.
Article in Portuguese | LILACS | ID: biblio-1352320

ABSTRACT

Diante da prevalência de distúrbios do controle glicêmico nas internações hospitalares, especialmente em pacientes portadores de diabetes mellitus, foram elaborados, pela equipe de endocrinologia do Hospital Geral Roberto Santos, protocolos informativos para padronização de condutas no manejo da hiperglicemia em pacientes críticos, não críticos e também para manejo de hipoglicemia no ambiente hospitalar. Trata-se de orientações elaboradas por médicos do corpo clínico da endocrinologia voltadas para os profissionais de saúde de todos os setores hospitalares, fundamentadas na importância crucial do correto manejo glicêmico de pacientes graves, internados em unidade de terapia intensiva, bem como daqueles sob cuidados médicos nos leitos de enfermaria, durante internação hospitalar. Além disso, diante do grande risco e da morbimortalidade associados aos episódios de hipoglicemia, preconizou-se a elaboração de um fluxo de conduta ágil e assertivo em caso de hipoglicemia. O tratamento objetivo e eficaz nesses cenários impacta fortemente o prognóstico dos pacientes, os desfechos clínicos e o tempo de internação. Palavras-chave: Hiperglicemia. Hipoglicemia. Complicações do diabetes.


Due to the prevalence of glycemic control in inpatients, especially diabetic patients, the Endocrinology team of the Hospital Geral Roberto Santos elaborated informative protocols for standardizing the management of hyperglycemia in critical and noncritical patients, as well as of hypoglycemia. Developed by endocrinologists and aimed at health professionals from all sectors, the protocols consist of orientations on the correct glycemic control in at-risk patients admitted to the Intensive Care Unit (ICU), as well as of nursing ward patients. Considering the high risk and morbimortality associated with hypoglycemia episodes, the protocol also preconizes the elaboration of a quick and assertive conduct. Objective and effective treatment in these scenarios strongly impacts prognoses, outcomes, and length of hospital stay.


Dada la prevalencia de trastornos del control glucémico en los ingresos hospitalarios, especialmente en pacientes con diabetes mellitus, el equipo de Endocrinología del Hospital Geral Roberto Santos creó protocolos informativos para estandarizar la conducta en el manejo de la hiperglucemia en pacientes críticos, no críticos y también para el manejo de hipoglucemia en el hospital. Se trata de guías elaboradas por médicos del cuadro clínico de endocrinología, dirigidas a profesionales de la salud de todos los sectores hospitalarios, basadas en la crucial importancia del correcto manejo glucémico de los pacientes críticos hospitalizados en la Unidad de Cuidados Intensivos; así como aquellos bajo atención médica en las camas de la sala durante la hospitalización. Además, dado el alto riesgo y la morbimortalidad asociados a los episodios de hipoglucemia, se recomendó el desarrollo de un flujo de conducta ágil y asertivo en caso de hipoglucemia. El tratamiento objetivo y eficaz en estos escenarios tiene un fuerte impacto en el pronóstico de los pacientes, la evolución clínica y la estancia hospitalaria.


Subject(s)
Indicators of Morbidity and Mortality , Diabetes Complications , Diabetes Mellitus , Glycemic Control , Hyperglycemia , Inpatients
6.
Rev. baiana saúde pública ; 45(3,supl.n.esp): 24-38, 28 dec. 2021.
Article in Portuguese | LILACS | ID: biblio-1352322

ABSTRACT

O período gestacional é caracterizado por diversas alterações metabólicas, dentre elas, a hiperglicemia, que confere uma importante condição, muitas vezes associada a desfechos desfavo[1]ráveis tanto para mãe como para o bebê. Diante desse cenário, a manutenção de um bom controle glicêmico se faz necessária, visando diminuir a morbimortalidade perinatal e a morbidade materna em curto e longo prazo. Devido à ausência de um consenso sobre esse manejo, o objetivo deste trabalho foi compilar as melhores práticas publicadas na literatura, no período de 2009 até 2021, para o manejo da hiperglicemia durante a gestação e sugerir um protocolo para o manejo da hiper[1]glicemia intra-hospitalar de gestantes a ser adotado em um hospital público de Salvador, na Bahia.


Pregnancy is characterized by several metabolic alterations, among which hyperglycemia is often associated with unfavorable outcomes for both mother and baby. In this scenario, maintaining a good glycemic control is necessary to reduce perinatal morbidity and maternal morbidity in the short- and long-term. Considering the lack of consensus regarding such a management, this work sought to compile the best management practices for hyperglycemia during pregnancy published in the literature from 2009 to 2021, as well as to suggest a new protocol to be adopted in a public hospital in Salvador, Bahia.


El período gestacional se caracteriza por varias alteraciones metabólicas, entre las cuales la hiperglucemia confiere una condición importante a menudo asociada con resultados desfavorables tanto para la madre como para el bebé. En este escenario, es necesario mantener un buen control glucémico para reducir la morbilidad perinatal y la morbilidad materna a corto y largo plazo. Debido a la falta de consenso sobre este manejo, el objetivo de este trabajo fue recopilar las mejores prácticas publicadas en la literatura, de 2009 a 2021, en cuanto al manejo de la hiperglucemia durante el embarazo, y proponer un protocolo para el manejo de la hiperglucemia interhospitalaria a gestantes, para ser adoptado en un hospital público de Salvador, Bahía.


Subject(s)
Morbidity , Pregnancy, High-Risk , Glycemic Control , Hyperglycemia
7.
Rev. cuba. med. mil ; 50(3): e1369, 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1357299

ABSTRACT

Introducción: Existen evidencias respecto a la relación inversa, entre la adherencia a la dieta mediterránea y el desarrollo de padecimientos crónicos como enfermedad coronaria, síndrome metabólico y diabetes. Objetivo: Determinar los factores bioquímicos asociados a la adherencia a la dieta mediterránea, en pacientes atendidos en un centro médico peruano. Métodos: Estudio transversal en 209 pacientes atendidos en un centro médico de Lima, Perú. Se utilizó el cuestionario PREDIMED para medir la adherencia a la dieta mediterránea. Se indagó la correlación entre el puntaje de adherencia a la dieta mediterránea y las covariables, edad, sexo, hipertrigliceridemia, hipercolesterolemia, hiperglicemia en ayunas y diagnóstico nutricional. Se utilizaron modelos lineales generales. Resultados: De 209 participantes, la mayoría fueron hombres (79,9 por ciento) y la mediana de edad fue de 31 años. El 20,2 por ciento tenía obesidad, quienes presentaron alteraciones en triglicéridos, fueron el 29,1 por ciento, colesterol (21,7 por ciento) y glicemia en ayunas (26,8 por ciento). En cuanto al puntaje del PREDIMED, la media fue de 4,6 puntos. Se encontró que la hiperglicemia en ayunas (Coef. = -2,08) tuvo asociación negativa con el puntaje de adherencia a la dieta mediterránea. Conclusión: La adherencia al patrón de dieta mediterránea es baja, y se correlaciona de forma negativa con hallazgos de hiperglicemia en los participantes evaluados (AU)


Introduction: There is evidence regarding the inverse relationship between adherence to the Mediterranean diet and the development of chronic conditions such as coronary heart disease, metabolic syndrome and diabetes. Objective: To determine the factors associated with adherence to the Mediterranean diet in patients attended in a Peruvian medical center. Methods: Cross-sectional analytical study in 209 patients attended at a medical center in Lima, Peru. The PREDIMED questionnaire was used to measure adherence to Mediterranean diet. Correlation between the Mediterranean diet adherence score and the covariates, age, sex, hypertriglyceridemia, hypercholesterolemia, fasting hyperglycemia and nutritional diagnosis was investigated. General linear models were used. Results: Of 209 participants, the majority were male (79.9 %) and the median age was 31 years. The 20.2 percent had obesity, those who presented alterations in triglycerides were 29.1 percent, cholesterol (21.7 percent) and fasting glycemia (26.8 percent). As for the PREDIMED score, the mean was 4.6 points. It was found that fasting hyperglycemia (Coef. = -2.08) had a negative association with the Mediterranean diet adherence score. Conclusion: Adherence to the Mediterranean diet pattern is low, and is negatively correlated with hyperglycemia findings in the participants evaluated(AU)


Subject(s)
Humans , Metabolic Syndrome , Diet, Mediterranean , Hypercholesterolemia , Hyperglycemia
8.
Rev. cuba. med ; 60(3): e1343, 2021. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1347508

ABSTRACT

Introducción: La hiperglucemia de ayuno es un factor pronóstico en cirugía. Encontrar el umbral de riesgo mayor en cirugía cardiovascular es una necesidad en la práctica médica actual. Objetivo: Estimar el umbral glucémico ideal de ayuno para un mejor pronóstico en la evolución clínica de los pacientes sometidos a cirugía cardiaca. Métodos: Se realizó un estudio descriptivo prospectivo en pacientes sometidos a cirugía cardíaca, en el Hospital Hermanos Ameijeiras durante el periodo de enero a junio del año 2017. La muestra quedó constituida por 191 pacientes, a todos los pacientes se les determinó glucemia de ayuno. Se empleó la prueba de independencia Ji-cuadrado (X2) para evaluar la asociación entre variables. Se realizó un análisis de regresión logística para identificar el efecto independiente de las variables estudiadas. Además, se construyó una curva Receiver Operating Characteristic Curve (por sus siglas en inglés) en la que se graficaron especificidad 1 y sensibilidad para cada punto de corte definido para los valores glucémicos. Resultados: La edad de los pacientes predominó entre 40-69 años, el sexo masculino representó 60,7 por ciento de la muestra, el 55,5 por ciento presentó glucemias normales y solo el 1,6 por ciento presentó glucemias mayores a 15 mmol/L. El 33,5 por ciento presentó algún tipo de complicación, los pacientes que presentaron complicaciones tenían la glucemia por encima de 9,9 mmol/L en el 84,4 por ciento. En el análisis multivariado solo hubo significación estadística para la aparición de complicaciones para la glucemia mayor a 10 mmol/L. Conclusiones: La hiperglucemia de ayuno se asoció a mayor riesgo de complicaciones(AU)


Introduction: Fasting hyperglycemia is a prognostic factor in surgery. Finding the highest risk threshold in cardiovascular surgery is a necessity in current medical practice. Objective: To estimate the ideal fasting glycemic threshold for a better prognosis in the clinical evolution of patients undergoing cardiac surgery. Methods: A prospective descriptive study was carried out in patients undergoing cardiac surgery, at Hermanos Ameijeiras Hospital from January to June 2017. The sample consisted of 191 patients; fasting blood glucose was determined in all patients. The Chi-square (X2) test of independence was used to evaluate the association between variables. A logistic regression analysis was performed to identify the independent effect of the variables studied. In addition, a Receiver Operating Characteristic Curve was constructed in which 1-specificity and sensitivity were plotted for each cut-off point defined for the glycemic values. Results: The 40-69 years age of the patients predominated, the male sex represented 60.7 percent of the sample, 55.5 percent had normal blood glucose levels and only 1.6 percent showed blood glucose levels higher than 15 mmol/L. Moreover, 33.5 percent had some type of complication; the patients with complications had blood glucose levels above 9.9 mmol/L in 84.4 percent. In the multivariate analysis, there was only statistical significance for the appearance of complications for glycaemia higher than 10 mmol/L. Conclusions: Fasting hyperglycemia was associated with higher risk of complications(AU)


Subject(s)
Humans , Prognosis , Thoracic Surgery/methods , Hyperglycemia , Epidemiology, Descriptive , Prospective Studies
9.
Rev. cuba. endocrinol ; 32(2): e285, 2021. graf
Article in Spanish | LILACS, CUMED | ID: biblio-1347405

ABSTRACT

Introducción: El páncreas ectópico es la segunda anomalía congénita pancreática más frecuente después del páncreas divisum. Fue descrito por primera vez en 1729 por Schultz y se define como la presencia de tejido pancreático que carece de comunicación anatómica o vascular con el cuerpo principal del páncreas. La localización más frecuente es en el estómago (25 - 38 por ciento), seguido de duodeno, yeyuno e íleon. El 40 por ciento de los casos son sintomáticos y es más frecuente su presentación en varones en torno a la 5ª y 6ª década de la vida. Objetivo: Presentar un caso de páncreas ectópico diagnosticado a través de un estudio histológico tras realizada la cirugía. Presentación de caso: Presentamos el caso de una paciente compatible con hipoglucemia y cuyo estudio definitivo mostró la presencia de tejido pancreático ectópico en estómago, con resolución completa de los síntomas tras tratamiento quirúrgico. La anatomía patológica mostró una lesión nodular tumoral benigna (2,5 cm), constituida por tejido pancreático heterotópico, con presencia de páncreas exocrino con acinos. Páncreas endocrino con presencia de islotes de Langerhans y componente epitelial con ductos. Afectación desde la submucosa hasta la subserosa, con una pared muscular propia con hiperplasia muscular en relación a la heterotopía pancreática. La mucosa gástrica mostraba inflamación crónica leve con escasos folículos linfoides. Conclusiones: La presencia de páncreas ectópico es una entidad poco frecuente, pero a tener en cuenta en pacientes con clínica de hipoglucemia, una vez descartadas otras causas. No existe consenso con respecto a indicaciones en el manejo de lesiones pequeñas y asintomáticas, por lo que se recomienda individualizar cada caso teniendo en cuenta el tamaño, la localización y el tipo histológico(AU)


Introduction: Ectopic pancreas is the second most frequent congenital anomaly after pancreas divisum. It was described for the first time in 1729 by Schultz and it is defined as the presence of pancreatic tissue with no anatomical or vascular communication with the main body of pancreas. The most common location is in the stomach (25-38 percent), followed by the duodenum, jejunum and ileum ones. 40 percent of the cases are symptomatic and is more frequent their presentation in males in the fifth or sixth decade of life. Objective: To present a case of ectopic pancreas diagnosed through a histological study after surgery. Case presentation: Case of a patient with clinical features compatible with hypoglycemia that after being studied showed the presence of ectopic pancreatic tissue in the stomach, with a complete solution of the symptoms after surgical treatment. The pathological anatomy showed a benign tumor nodular lesion (2.5 cm), made up of heterotopic pancreatic tissue, with the presence of exocrine pancreas with acini. Endocrine pancreas with the presence of islets of Langerhans and epithelial component with ducts. Involvement from the submucosa to the subserosa, with a proper muscular wall with muscular hyperplasia in relation to pancreatic heterotopia. The gastric mucosa showed mild chronic inflammation with few lymphoid follicles. Conclusions: The presence of ectopic pancreas is a rare condition, but it should be taken into account in patients with clinical features of hypoglycemia once ruled out other causes. There is no consensus in regards to the indications for the management of small and asymptomatic lesions, so, it is recommended to individualize each case taking into account the size, location and histological type(AU)


Subject(s)
Humans , Female , Adult , Pancreas/abnormalities , Stomach/injuries , Islets of Langerhans/abnormalities , Hyperglycemia/etiology
10.
Rev. med. Risaralda ; 27(1): 56-63, ene.-jun. 2021. tab
Article in Spanish | LILACS, COLNAL | ID: biblio-1280493

ABSTRACT

Resumen Objetivo: Describir el tratamiento en un hospital de primer nivel de pacientes que consultaron el servicio de urgencias por hiperglucemia, el manejo previo y su probable relación con nuevas hiperglucemias. Materiales y métodos: Estudio observacional de corte transversal con seguimiento de un año en pacientes mayores de 18 años con hiperglucemia que consultaron en el servicio de urgencias entre septiembre-2016 y agosto-2017. Se revisaron las historias clínicas y se establecieron variables sociodemográficas, clínicas, y farmacológicas. Se empleó estadística descriptiva, X 2 y modelos de regresión logística binaria (P<0.05). Resultados: Se presentaron 86 pacientes con hiperglucemia (edad media de 52.1±14.93 años). Se encontró que en el 58,1% de casos había un diagnóstico previo de diabetes mellitus; 87,2% fueron tratados con insulina cristalina y el 47,0% de los pacientes consultaron nuevamente por una crisis de hiperglucemia en los seis meses posteriores al egreso. Conclusión: Existe alta proporción de pacientes con hiperglucemias no cetónicas, no hiperosmolares que desconocían presentar diabetes mellitus. Además, casi la mitad de los pacientes consultan nuevamente por crisis de hiperglucemia en los siguientes seis meses después del alta.


Abstract Objective: Describe the treatment in a first-level hospital of patients who consulted the emergency department for hyperglycemia, the previous management and its probable relationship with new hyperglycemia. Materials and methods: Observational cross-sectional study with a one-year follow-up in patients over 18 years of age with hyperglycemia who consulted in the emergency department between September-2016 and August-2017. The medical records were reviewed and sociodemographic, clinical, and pharmacological variables were established. Descriptive statistics, X2 and binary logistic regression models (P <0.05) were used. Results: There were 86 patients with hyperglycemia (mean age 52.1 ± 14.93 years). It was found that in 58.1% of cases there was a previous diagnosis of diabetes mellitus; 87.2% were treated with crystalline insulin and 47.0% of the patients consulted again for a hyperglycemic crisis in the six months after discharge. Conclusion: There is a high proportion of patients with non-ketonic, non-hyperosmolar hyperglycemia who were unaware of having diabetes mellitus. In addition, almost half of the patients consult again for a hyperglycemic attack in the following six months after discharge.


Subject(s)
Humans , Female , Middle Aged , Pharmacoepidemiology , Diabetes Mellitus , Hospitals , Hyperglycemia , Insulin , Therapeutics , Aftercare , Emergencies , Emergency Service, Hospital
11.
Rev. cuba. endocrinol ; 32(1): e154, 2021.
Article in Spanish | LILACS, CUMED | ID: biblio-1289389

ABSTRACT

La evidencia clínica que ha permitido relacionar la diabetes mellitus con la infertilidad se basa en la importancia del metabolismo de la glucosa durante el proceso de espermatogénesis, debido a que en los episodios tanto de hipoglucemia como de hiperglucemia pueden ocurrir cambios epigenéticos en algunas proteínas involucradas en la espermatogénesis. En la presente comunicación se describen los aspectos teóricos de los efectos de la diabetes sobre el líquido seminal con énfasis en la espermatogénesis(AU)


The clinical evidence that has made it possible to link diabetes mellitus with infertility is based on the importance of glucose metabolism during the spermatogenesis process, because in episodes of both hypoglycemia and hyperglycemia, epigenetic changes can occur in some proteins involved in spermatogenesis. This communication describes the theoretical aspects of the effects of diabetes on seminal fluid with emphasis on spermatogenesis(AU)


Subject(s)
Humans , Spermatogenesis , Diabetes Mellitus/epidemiology , Hyperglycemia/etiology , Hypoglycemia/etiology , Infertility/therapy
12.
Rev. Asoc. Odontol. Argent ; 109(1): 64-72, ene.-abr. 2021. tab
Article in Spanish | LILACS | ID: biblio-1281783

ABSTRACT

La diabetes mellitus es una enfermedad metabólica caracterizada por altos niveles de glucosa en sangre y defectos en la producción y/o la acción de la insulina. La hiperglucemia crónica puede derivar en complicaciones metabólicas y vasculares como micro- y macroangiopatías y alteraciones en el metabolismo de lípidos y proteínas. Los pacientes diabéticos mal controlados o no controlados presentan signos y síntomas evidenciables a nivel bucal. En el mundo, alrededor del 8,8% de los adultos de entre 20 y 79 años padecen este trastorno endócrino, y se estima que para el año 2045 unos 629 millones de personas de este rango etario tendrán diabetes. Por ello, es fundamental que el odontólogo se encuentre familiarizado con el manejo médico de estos pacientes, a fin de estar preparado para brindarles un tratamiento adecuado y responder a las emergencias médicas que se presenten durante su atención. En esta revisión se emplearon resultados extraídos manualmente de artículos indexados en las bases de datos MEDLINE y EBSCO que responden a la búsqueda de los términos diabetes mellitus, dental management, oral surgery y HbA1c, con el objetivo de describir el manejo médico-odontológico del paciente diabético hasta la fecha (AU)


Diabetes Mellitus is a metabolic disease characterized by high blood glucose levels and defects in the production and/or the use of insulin. Chronic hyperglycemia can lead to metabolic and vascular complications. Vascular complications include micro and macroangiopathies. The metabolic disorders are: alterations of lipid and protein metabolism. Patients with poorly controlled or uncontrolled diabetes present symptoms that are evident in the oral cavity. Around 8.8% of adults between 20-79 years old, worldwide, have this endocrine disorder and it is estimated that by 2045, 629 million people in this age group, will have diabetes. Therefore, it is essential for dentists to be familiar with the medical management of these patients, in order to provide adequate treatment and eventual management of medical emergencies that may occur during dental treatment. The present review used data extracted manually from articles indexed in the MEDLINE and EBSCO databases, using the terms: Diabetes mellitus, Dental Management, Oral Surgery and HbA1c. The following article aims to describe the medical/dental management of the diabetic patient updated to date (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Dental Care for Chronically Ill/methods , Diabetes Complications , Diabetes Mellitus/pathology , Surgery, Oral/methods , Glycated Hemoglobin A , Databases, Bibliographic , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Hyperglycemia/complications
13.
Arq. bras. cardiol ; 116(3): 415-422, Mar. 2021. graf
Article in English, Portuguese | LILACS | ID: biblio-1248864

ABSTRACT

Resumo Fundamento: É sabido que a resistência à insulina e a hiperglicemia são causas patológicas importantes no desenvolvimento de cardiomiopatia diabética (CMD). Entretanto, seus mecanismos moleculares precisos na patogênese da CMD ainda não estão claros. Objetivos: Estudos recentes revelam que os microRNAs (miRNAs) desempenham papéis essenciais na patogênese da CMD. Este projeto tem o objetivo de determinar os papéis de miR-34a e miR-125b na morte celular de cardiomiócitos causada por hiperglicemia. Métodos: Cardiomiócitos primários de ratos foram isolados e expostos a concentrações de glicose normais e altas. A viabilidade das células foi medida utilizando-se o ensaio MTT. As expressões de miR-34a e miR-125b foram detectadas por qRT-PCR. Alvos potenciais de miR-34a e miR-125b foram previstos pelo www.Targetscan.org, e validados a partir de tecidos cardíacos humanos. Um p<0,05 foi considerado significância estatística. Resultados: Demonstra-se neste estudo que o miR-34a e o miR-125b têm resposta celular reduzida no coração humano diabético. Além disso, os dados in vitro de cardiomiócitos primários de ratos demonstraram que o tratamento com glicose alta em curto prazo estimula a expressão de miR-34a e miR-125b. Demonstrou-se que, em condições de glicose alta, os cardiomiócitos de ratos apresentaram metabolismo de glicose intracelular, e a captação de glicose e a produção de lactato aumentaram significativamente. Foi identificado que as principais enzimas metabólicas da glicose, hexoquinase 2 (HK2) e lactato desidrogenase-A (LDHA) eram alvos diretos de miR-125b e miR-34a, respectivamente. A superexpressão de miR-125b e miR-34a poderia evitar a morte de celular de cardiomiócitos causada por hiperglicemia. Por fim, a recuperação de HK2 e LDHA em cardiomiócitos com superexpressão de miR-125b e miR-34a restaurou a sensibilidade de cardiomiócitos à hiperglicemia. Conclusões: Nossos resultados propõem um mecanismo molecular para proteção cardiovascular diabética mediada por microRNA e contribuirão para o desenvolvimento de estratégias de tratamento de disfunção cardiovascular associada a diabetes.


Abstract Background: It is well-known that insulin resistance and hyperglycemia are important pathological causes for the development of diabetic cardiomyopathy (DCM). However, its precise molecular mechanisms in the pathogenesis of DCM remain unclear. Objectives: Recent studies reveal that microRNAs (miRNA) play essential roles in the pathogenesis of DCM. This project aimed to determine the roles of miR-34a and miR-125b in hyperglycemia-induced cardiomyocyte cell death. Methods: Rat primary cardiomyocytes were isolated and exposed to normal and high concentrations of glucose. Cell viability was measured using MTT assay. Expressions of miR-34a and miR-125b were detected by qRT-PCR. Potential targets of miR-34a and miR-125b were predicted from www.Targetscan.org and validated from human heart tissues. A statistical significance of p<0.05 was considered. Results: The present study shows that miR-34a and miR-125b are downregulated in a human diabetic heart. Moreover, in vitro data from rat primary cardiomyocytes showed that short-term high glucose treatment stimulates miR-34a and miR-125b expressions. Under high glucose, it was found that rat cardiomyocytes displayed increased intracellular glucose metabolism, and glucose uptake and lactate production were significantly increased. It was also found that the key glucose metabolic enzymes, Hexokinase 2 (HK2) and Lactate dehydrogenase-A (LDHA), were direct targets of miR-125b and miR-34a, respectively. Overexpression of miR-125b and miR-34a could prevent hyperglycemia-induced cardiomyocyte cell death. Finally, the restoration of HK2 and LDHA in miR-125b and miR-34a overexpressed cardiomyocytes recovered the cardiomyocytes' sensitivity to hyperglycemia. Conclusion: Our results proposed a molecular mechanism for the microRNA-mediated diabetic cardiovascular protection and will contribute to developing treatment strategies for diabetes-associated cardiovascular dysfunction.


Subject(s)
Animals , Rats , MicroRNAs/genetics , Hyperglycemia , Cell Death , Myocytes, Cardiac , Glucose
14.
Rev. bras. ginecol. obstet ; 43(2): 107-112, Feb. 2021. tab
Article in English | LILACS | ID: biblio-1156093

ABSTRACT

Abstract Objective To evaluate the obstetric and sociodemographic characteristics of gestational diabetic women who maintained hyperglycemia in the postpartum period (6-12 weeks postpartum). Methods This is a longitudinal cohort study with women who have had gestational diabetes and/or macrosomic children between March 1st, 2016 and March 1st, 2017. Between 6 and 12 weeks after birth, women who had gestational diabetes collected fasting glycemia, glucose tolerance test, and glycated hemoglobin results. The data were collected from medical records and during an interview in the first postpartum consultation. A statistical analysis was performed using frequency, percentage, Chi- Squared test, Fisher exact test, Mann-Whitney test, and multivariate Poisson regression. The significance level adopted for the statistical tests was 5%. Results One hundred and twenty-two women were included. Most of the women were younger than 35 years old (70.5%), white, multiparous, and with no history of gestational diabetes. Thirteen percent of the participants developed persistent hyperglycemia. A univariate analysis showed that maternal age above 35 years, being overweight, having grade 1 obesity and weight gain under 5 kg was related to the persistence of hyperglycemia in the postpartum period. Conclusion Maternal age above 35 years, obesity and overweight, and the diagnosis of gestational diabetes in the first trimester of pregnancy are associated with hyperglycemia during the postpartum period.


Resumo Objetivo Avaliar características sociodemográficas e obstétricas de mulheres com diabetes gestacional que mantêm hiperglicemia no período pós-parto (6-12 semanas pós-parto). Métodos Este é um estudo longitudinal de coorte com mulheres com diagnóstico de diabetes gestacional e/ou macrossomia fetal entre 1° de março de 2016 a 1° de março de 2017. As mulheres coletaram glicemia de jejum, teste de tolerância a glicose e hemoglobina glicada entre 6 a 12 semanas pós-parto. Os dados foram coletados de prontuários médicos e durante entrevista na primeira consulta de revisão pós-parto. Uma análise estatística foi realizada através do cálculo de frequências, porcentagens, teste do qui-quadrado, teste exato de Fisher, teste de Mann-Whitney e regressão multivariada de Poisson. A significância estatística adotada foi de 5%. Resultados Cento e vinte e duas mulheres foram incluídas. A maioria delas tinha menos de 35 anos de idade (70,5%), eram brancas, multíparas, e não tinham história de diabetes gestacional. Treze por cento das participantes desenvolveu hiperglicemia persistente. A análise univariada mostrou que os fatores relacionados com a persistência de hiperglicemia no período pós-natal foram: idade materna acima de 35 anos, sobrepeso, obesidade grau 1 e ganho de peso abaixo de 5 quilos. A análisemultivariada incluiu o diagnóstico no primeiro trimestre como fator de risco para hiperglicemia persistente. Conclusão Mulheres acima de 35 anos, obesidade, sobrepeso e diagnóstico de diabetes gestacional no primeiro trimestre estão relacionados com hiperglicemia persistente no período pós-parto.


Subject(s)
Humans , Female , Pregnancy , Adult , Young Adult , Puerperal Disorders/epidemiology , Diabetes, Gestational/physiopathology , Hyperglycemia/physiopathology , Obesity/physiopathology , Pregnancy Complications/physiopathology , Pregnancy Trimester, First , Puerperal Disorders/physiopathology , Puerperal Disorders/blood , Socioeconomic Factors , Blood Glucose , Brazil/epidemiology , Glycated Hemoglobin A , Cohort Studies , Longitudinal Studies , Hyperglycemia/blood
15.
Arq. bras. cardiol ; 116(2): 285-294, fev. 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1153009

ABSTRACT

Resumo Fundamento O maior risco de se desenvolver diabetes com o uso de estatinas é um desafio para a segurança do uso dessa classe de medicamentos em longo prazo. No entanto, poucos estudos analisaram essa questão durante síndromes coronarianas agudas (SCA). Objetivos Investigar a associação entre início precoce da terapia com estatina e níveis de glicemia em pacientes admitidos com SCA. Métodos Este foi um estudo retrospectivo de pacientes hospitalizados por SCA. Pacientes que nunca haviam usado estatinas foram incluídos e divididos segundo uso ou não de estatina nas primeiras 24 horas de internação. O desfecho primário foi a incidência de hiperglicemia na internação (definida como pico de glicemia > 200mg/dL). Modelos de regressão logística e modelos lineares multivariados foram usados para ajuste quanto a fatores de confusão e um modelo de pareamento por escore de propensão foi desenvolvido para comparações entre os dois grupos de interesses. Um valor de p menor que 0,05 foi considerado estatisticamente significativo. Resultados Um total de 2357 pacientes foram incluídos, 1704 deles alocados no grupo que receberam estatinas e 653 no grupo que não receberam estatinas nas primeiras 24 horas de internação. Após os ajustes, uso de estatina nas primeiras 24 horas foi associado com uma menor incidência de hiperglicemia durante a internação (OR ajustado = 0,61, IC95% 0,46-0,80; p < 0,001) e menor necessidade de uso de insulina (OR ajustado = 0,56, IC 95% 0,41-0,76; p < 0,001). Essas associações mantiveram-se similares nos modelos de pareamento por escore de propensão, bem como após análises de sensibilidade, como exclusão de pacientes que desenvolveram choque cardiogênico, infecção grave ou pacientes que foram a óbito durante a internação hospitalar. Conclusões Entre os pacientes internados com SCA que não receberam estatinas previamente, a terapia precoce com estatina associou-se independentemente com menor incidência de hiperglicemia durante a internação. (Arq Bras Cardiol. 2021; 116(2):285-294)


Abstract Background Increased risk of new-onset diabetes with statins challenges the long-term safety of this drug class. However, few reports have analyzed this issue during acute coronary syndromes (ACS). Objective To explore the association between early initiation of statin therapy and blood glucose levels in patients admitted with ACS. Methods This was a retrospective analysis of patients hospitalized with ACS. Statin-naïve patients were included and divided according to their use or not of statins within the first 24 hours of hospitalization. The primary endpoint was incidence of in-hospital hyperglycemia (defined as peak blood glucose > 200 mg/dL). Multivariable linear and logistic regression models were used to adjust for confounders, and a propensity-score matching model was developed to further compare both groups of interest. A p-value of less than 0.05 was considered statistically significant. Results A total of 2,357 patients were included, 1,704 of them allocated in the statin group and 653 in the non-statin group. After adjustments, statin use in the first 24 hours was associated with a lower incidence of in-hospital hyperglycemia (adjusted OR=0.61, 95% CI 0.46-0.80; p < 0.001) and lower need for insulin therapy (adjusted OR = 0.56, 95% CI 0.41-0.76; p < 0.001). These associations remained similar in the propensity-score matching models, as well as after several sensitivity analyses, such as after excluding patients who developed cardiogenic shock, severe infection or who died during index-hospitalization. Conclusions Among statin-naïve patients admitted with ACS, early statin therapy was independently associated with lower incidence of in-hospital hyperglycemia. (Arq Bras Cardiol. 2021; 116(2):285-294)


Subject(s)
Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Acute Coronary Syndrome/prevention & control , Acute Coronary Syndrome/epidemiology , Hyperglycemia/epidemiology , Incidence , Retrospective Studies , Follow-Up Studies
16.
Ciênc. Saúde Colet ; 26(2): 531-540, fev. 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1153803

ABSTRACT

Resumo O objetivo deste estudo foi avaliar a prevalência de pré-diabetes e hiperglicemia intermediária em adultos brasileiros, considerando diferentes critérios diagnósticos, e estabelecer fatores associados à sua ocorrência. Análise dos dados laboratoriais da Pesquisa Nacional de Saúde, coletados em 2014 e 2015. Foram calculadas as prevalências das condições conforme critérios da Associação Americana de Diabetes (ADA) - Hemoglobina Glicada (HbA1c) 5,7 a 6,4% - e da Organização Mundial de Saúde (OMS), de 6 - 6,4% entre aqueles que não tinham critério para diabetes. Razões de prevalência (RP) brutas e ajustadas e IC 95% foram calculados por regressão de Poisson com variância robusta. A prevalência de pré-diabetes pelo critério ADA foi de 18,5% e de 7,5% pelo critério da OMS. Verificou-se um gradiente de aumento das prevalências segundo a idade da população e presença de fatores de risco como hipertensão arterial, obesidade, circunferência abdominal elevada e baixo colesterol HDL. Os menos escolarizados e os declarados pretos apresentaram prevalências superiores. Este estudo aponta um intervalo entre 7,5 a 18,5% de adultos brasileiros que apresentam pré-diabetes e hiperglicemia intermediária, além de identificar um escore de risco para a ocorrência dessa condição.


Abstract This study aimed to evaluate the prevalence of prediabetes and intermediate hyperglycemia in Brazilian adults, according to different diagnostic criteria, and establish associated factors to its occurrence. We analyzed the National Health Survey laboratory data collected from 2014 to 2015. The prevalence of the conditions was calculated according to the American Diabetes Association (ADA) diagnostic criteria based on glycated hemoglobin (HbA1c) 5.7%-6.4%, and the World Health Organization (WHO) 6-6.4%, among those without criteria for diabetes. Crude and adjusted prevalence rates (PR) and 95% CI were calculated using Poisson regression with robust variance. The prevalence of prediabetes by ADA and WHO criteria was 18.5 and 7.5%, respectively. We observed a gradient of increased prevalence by the age of the population and risk factors, like arterial hypertension, obesity, elevated waist circumference, and low HDL cholesterol levels. Less educated people and the self-declared black had a higher prevalence. This study pointed out a range from 7.5 to 18.5% of Brazilian adults with prediabetes and intermediate hyperglycemia and identified a risk score to this condition's occurrence.


Subject(s)
Humans , Adult , Prediabetic State/epidemiology , Hyperglycemia/epidemiology , Blood Glucose , Brazil/epidemiology , Prevalence , Risk Factors , Health Surveys
17.
Rev. bras. ter. intensiva ; 33(1): 138-145, jan.-mar. 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1289066

ABSTRACT

RESUMO Objetivo: Duplicar a percentagem de tempo no intervalo glicêmico 100 - 180mg/dL nos primeiros 3 meses após implementação faseada de um programa de educação formal e, posteriormente, de um protocolo de insulinoterapia, sem condicionar um aumento da frequência de hipoglicemia. Métodos: Foi feita a avaliação retrospetiva do controle glicêmico pré-intervenção. Foram realizados: implementação de um programa formal de educação; distribuição de algoritmos manuais de insulinoterapia endovenosa - otimizados pelos utilizadores, a partir do protocolo de Yale modificado - e formação informal da equipe de enfermagem. Foi dado apoio à utilização dos sistemas eletrônicos de controle glicêmico e do registo prospetivo dos resultados. Resultados: A primeira fase do programa (educação formal) melhorou o tempo no intervalo euglicêmico (28% para 37%). A segunda fase permitiu atingir 66% do tempo de euglicemia, com diminuição das hipoglicemias. A percentagem de doentes sob perfusão endovenosa de insulina às 48 horas de internamento aumentou (6% para 35%). Conclusão: A implementação faseada de um programa formal de educação que favoreceu a aplicação de protocolos de insulinoterapia eletrônicos e manuais dinâmicos demonstrou ter aderência e ser segura e eficaz no controle glicêmico no doente crítico, com diminuição concomitante das hipoglicemias.


ABSTRACT Objective: To double the percentage of time within the 100 - 180mg/dL blood glucose range in the first three months following a phased implementation of a formal education program, and then, of an insulin therapy protocol, without entailing an increased incidence of hypoglycemia. Methods: The pre-intervention glycemic control was assessed retrospectively. Next, were carried out the implementation of a formal education program, distribution of manual algorithms for intravenous insulin therapy - optimized by the users, based on the modified Yale protocol - and informal training of the nursing staff. The use of electronic blood glucose control systems was supported, and the results were recorded prospectively. Results: The first phase of the program (formal education) lead to improvement of the time within the euglycemic interval (28% to 37%). In the second phase, euglycemia was achieved 66% of the time, and the incidence of hypoglycemia was decreased. The percentage of patients on intravenous insulin infusion at 48 hours from admission increased from 6% to 35%. Conclusion: The phased implementation of a formal education program, fostering the use of electronic insulin therapy protocols and dynamic manuals, received good adherence and has shown to be safe and effective for blood glucose control in critically ill patients, with a concomitant decrease in hypoglycemia.


Subject(s)
Humans , Glycemic Control , Hyperglycemia/drug therapy , Hyperglycemia/epidemiology , Portugal , Blood Glucose , Retrospective Studies , Hypoglycemic Agents/adverse effects , Intensive Care Units
18.
Rev. Assoc. Med. Bras. (1992) ; 67(1): 45-51, Jan. 2021. tab, graf
Article in English | LILACS | ID: biblio-1287798

ABSTRACT

SUMMARY OBJECTIVE: To investigate sleep alterations and associated factors in pregnant diabetic women (n=141). METHODS: Sleep profile, sociodemographics and clinical information were collected. Poor sleep quality (Pittsburgh Sleep Quality Index >5) and excessive daytime sleepiness (Epworth Sleepiness Scale ≥10), sleep duration (h), sleep latency (min), frequent sleep interruption and short sleep (≤6 h) were assessed in type 1 diabetes mellitus (16.3%), type 2 diabetes mellitus (25.5%) and gestational diabetes mellitus (58.2%). RESULTS: Poor sleep quality was found in 58.8% of patients and daytime sleepiness in 25.7%, regardless of hyperglycemia etiology. No correlation existed between daytime sleepiness and poor sleep quality (Pearson correlation r=0.02, p=0.84). Short sleep duration occurred in 1/3 of patients (31.2%). Sleep interruptions due to frequent urination affected 72% of all and sleep interruptions due to any cause 71.2%. Metformin was used by 65.7% of type 2 diabetes mellitus and 28.7% of gestational diabetes mellitus. In gestational diabetes mellitus, parity number was independently associated with poor sleep quality (p=0.02; OR=1.90; 95%CI 1.07-3.36) and metformin use was also independently associated with poor sleep quality (p=0.03; OR=2.36; 95%CI 1.05-5.29). CONCLUSIONS: Our study originally shows that poor sleep quality and excessive daytime sleepiness are frequent in diabetic pregnancy due to different etiologies. Interestingly, only in gestational diabetes mellitus, metformin therapy and higher parity were associated with poor sleep quality.


Subject(s)
Humans , Female , Pregnancy , Sleep Wake Disorders/epidemiology , Diabetes, Gestational/drug therapy , Diabetes, Gestational/epidemiology , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/epidemiology , Hyperglycemia/epidemiology , Disorders of Excessive Somnolence , Sleep
19.
Chinese Medical Journal ; (24): 1695-1700, 2021.
Article in English | WPRIM | ID: wpr-887651

ABSTRACT

BACKGROUND@#Glucose control is an important aspect in managing critically ill patients. The goal of this study was to compare the effects of sequential feeding (SF) and continuous feeding (CF) on the blood glucose of critically ill patients.@*METHODS@#A non-inferiority randomized controlled trial was adopted in this study. A total of 62 patients who were fed enteral nutritional suspension through gastric tubes were enrolled. After achieving 80% of the nutrition target calories (25 kcal·kg-1·day-1) through CF, the patients were then randomly assigned into SF and CF groups. In the SF group, the feeding/fasting time was reasonably determined according to the circadian rhythm of the human body as laid out in traditional Chinese medicine theory. The total daily dosage of the enteral nutritional suspension was equally distributed among three time periods of 7 to 9 o'clock, 11 to 13 o'clock, and 17 to 19 o'clock. The enteral nutritional suspension in each time period was pumped at a uniform rate within 2 h by an enteral feeding pump. In the CF group, patients received CF at a constant velocity by an enteral feeding pump throughout the study. Blood glucose values at five points (6:00/11:00/15:00/21:00/1:00) were monitored and recorded for seven consecutive days after randomization. Enteral feeding intolerance was also recorded. Non-inferiority testing was adopted in this study, the chi-square test or Fisher test was used for qualitative data, and the Mann-Whitney U test was used for quantitative data to determine differences between groups. In particular, a repeated measure one-way analysis of variance was used to identify whether changes in glucose value variables across the time points were different between the two groups.@*RESULTS@#There were no significant demographic or physiological differences between the SF and CF groups (P > 0.050). The average glucose level in SF was not higher than that in CF (8.8 [7.3-10.3] vs. 10.7 [9.1-12.1] mmol/L, Z = -2.079, P for non-inferiority = 0.019). Hyperglycemia incidence of each patient was more common in the CF group than that in the SF group (38.4 [19.1-63.7]% vs. 11.8 [3.0-36.7]%, Z = -2.213, P = 0.027). Hypoglycemia was not found in either group. Moreover, there was no significant difference during the 7 days in the incidence of feeding intolerance (P > 0.050).@*CONCLUSIONS@#In this non-inferiority study, the average blood glucose in SF was not inferior to that in CF. The feeding intolerance in SF was similar to that in CF. SF may be as safe as CF for critically ill patients.@*TRIAL REGISTRATION@#ClinicalTrials.gov, NCT03439618; https://clinicaltrials.gov/ct2/show/record/NCT03439618.


Subject(s)
Blood Glucose , Critical Illness , Energy Intake , Enteral Nutrition , Humans , Hyperglycemia , Infant, Newborn
20.
Article in English | WPRIM | ID: wpr-922411

ABSTRACT

OBJECTIVES@#To study the effect of glucose metabolism disorders on the short-term prognosis in neonates with asphyxia.@*METHODS@#A retrospective analysis was performed on the medical data of the neonates with asphyxia who were admitted to 52 hospitals in Hubei Province of China from January to December, 2018 and had blood glucose data within 12 hours after birth. Their blood glucose data at 1, 2, 6, and 12 hours after birth (with an allowable time error of 0.5 hour) were recorded. According to the presence or absence of brain injury and/or death during hospitalization, the neonates were divided into a poor prognosis group with 693 neonates and a good prognosis group with 779 neonates. The two groups were compared in the incidence of glucose metabolism disorders within 12 hours after birth and short-term prognosis.@*RESULTS@#Compared with the good prognosis group, the poor prognosis group had a significantly higher proportion of neonates from secondary hospitals (48.5% vs 42.6%, @*CONCLUSIONS@#Recurrent hyperglycemia in neonates with asphyxia may suggest poor short-term prognosis, and it is necessary to strengthen the early monitoring and management of the nervous system in such neonates.


Subject(s)
Asphyxia , Asphyxia Neonatorum/epidemiology , Humans , Hyperglycemia , Infant, Newborn , Prognosis , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL